Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus.

The present study was undertaken to assess the role of tumor-associated urokinase-type plasminogen activator (uPA) and its inhibitor type 1 (PAI-1) as a predictor for early relapse and poor prognosis in patients with stage II cervical cancer of the uterus. We have investigated the localization of uPA and PAI-1 immunohistochemically in formalin-fixed paraffin-embedded tissue sections. uPA and PAI-1 were analyzed antigenically, enzymologically, and zymographically in 28 patients with pelvic lymph node involvement and in 34 cases without nodal spread, as well as in 10 cases with normal cervix. In cancer tissues, strong staining for uPA was found in areas with invasive growth and degradation of surrounding normal tissue, while most tumor nests showed a mild or a moderate, evenly distributed PAI-1 staining. A significantly higher lymph node-positive rate was observed in patients having tumors with strong uPA and/or PAI-1 stainings than in those with tumors with weak stainings. In spite of significantly higher PAI-1 levels in the primary neoplastic tissues, uPA was found to be increased as well, both in antigen level and in activity. Most of PAI-1 obtained from cancer extracts is the latent form. These results suggest that cancer-associated increase in uPA seems not to be affected (or inhibited) by PAI-1 in areas where tumor cells are invading normal tissue. The overall survival and progression-free survival rate was worst in patients with the strong uPA staining confined to the tumor stromas and also with the strong PAI-1 staining at tumor nests, indicating that the greater localization of uPA in stromal cells than in malignant cells is a predictor of early relapse and poor prognosis in patients with cervical cancer of the uterus. Thus, the staining intensities and the localization of uPA and PAI-1 in tissue specimens appear to be predictors of increasing risk for lymph node metastasis, suggesting that some tumor cells recruit stromal cells to produce uPA and that PAI-1 may not act as a defense mechanism for tumor cell invasion and metastasis in the leading edge of tumor growth.

[1]  T. Terao,et al.  Increased Cell‐surface Urokinase in Advanced Ovarian Cancer , 1993, Japanese journal of cancer research : Gann.

[2]  J. Foekens,et al.  Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. , 1992, Cancer research.

[3]  H. Kobayashi,et al.  Modulation of Urokinase-type Plasminogen Activator and Ovarian Cancer Cell Invasion by in Vitro Inhibition of Updated Version Citing Articles E-mail Alerts Inhibition of in Vitro Ovarian Cancer Cell Invasion by Modulation of Urokinase- Type Plasminogen Activator and Cathepsin B , 2022 .

[4]  A. Sumiyoshi,et al.  The content of urokinase‐type plasminogen activator antigen as a prognostic factor in urinary bladder cancer , 1992, International journal of cancer.

[5]  K. Hyde,et al.  Two-colour immunoenzymatic technique using sequential staining by APAAP to evaluate two cell antigens. , 1992, Journal of clinical pathology.

[6]  T. Urano,et al.  Plasminogen activator system in human breast cancer , 1992, International journal of cancer.

[7]  B. Alving,et al.  Plasminogen Activator Inhibitor Type 1: Biochemistry and Evidence for Modulation of Fibrinolysis In Vivo , 1992, Seminars in thrombosis and hemostasis.

[8]  P. Quax,et al.  Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis. , 1991, Gastroenterology.

[9]  P. Quax,et al.  Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation , 1991, The Journal of cell biology.

[10]  F. Jänicke,et al.  Clinical Relevance of the Urokinase-Type and Tissue-Type Plasminogen Activators and of Their Type 1 Inhibitor in Breast Cancer , 1991, Seminars in thrombosis and hemostasis.

[11]  K. Sugimachi,et al.  Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma. , 1991, Cancer research.

[12]  J. Calvete,et al.  Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). , 1991, The Journal of biological chemistry.

[13]  F. Blasi,et al.  Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. , 1991, The Journal of biological chemistry.

[14]  L. Kirkeby,et al.  Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. , 1991, The American journal of pathology.

[15]  B. Kudryk,et al.  Occurrence of components of fibrinolysis pathways in situ in neoplastic and nonneoplastic human breast tissue. , 1991, Cancer research.

[16]  M. Baker,et al.  Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation. , 1990, Cancer research.

[17]  D. Rifkin,et al.  Bimodal relationship between invasion of the amniotic membrane and plasminogen activator activity , 1990, International journal of cancer.

[18]  D. Boyd,et al.  Examination of the role of the urokinase receptor in human colon cancer mediated laminin degradation. , 1989, Cancer research.

[19]  M. Schmitt,et al.  UROKINASE-TYPE PLASMINOGEN ACTIVATOR ANTIGEN AND EARLY RELAPSE IN BREAST CANCER , 1989, The Lancet.

[20]  S. Kohga,et al.  Comparison of the immunohistochemical localisation of urokinase in normal and cancerous human colon tissue , 1989 .

[21]  L. Ossowski,et al.  In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase , 1988, The Journal of cell biology.

[22]  E. Appella,et al.  Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. , 1988, Cancer research.

[23]  P. Burtin,et al.  The plasmin system in human adenocarcinomas and their metastases. A comparative immunofluorescence study , 1987, International journal of cancer.

[24]  A. Corti,et al.  Differential Detection of Single-Chain and Two-Chain Urokinase-Type Plasminogen Activator by a New Immunoadsorbent-Amidolytic Assay (IAA) , 1986, Thrombosis and Haemostasis.

[25]  D. Rifkin,et al.  Tumor invasion through the human amniotic membrane: Requirement for a proteinase cascade , 1986, Cell.

[26]  D. Loskutoff,et al.  Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. , 1985, The Journal of biological chemistry.

[27]  S. Kohga,et al.  Localization of plasminogen activators in human colon cancer by immunoperoxidase staining. , 1985, Cancer research.

[28]  K. Danø,et al.  Plasminogen activators, tissue degradation, and cancer. , 1985, Advances in cancer research.

[29]  D. Lawrence,et al.  Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. , 1984, The Journal of biological chemistry.

[30]  L. Liotta,et al.  Tumor invasion and the extracellular matrix. , 1983, Laboratory investigation; a journal of technical methods and pathology.

[31]  E. Gehan.  A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES. , 1965, Biometrika.

[32]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .